Insights Advancing the Future of Pharmaceuticals

Disease-area strategy — Disease-area Strategy

Explore our Indication Prioritization and Disease-Area Scan tools

Business Development & Early R&D

Take a look at our Signature Disease Target Assessment (DTA)

Late-stage Development

Dive into our patient-share forecasting, patient-flow modeling, and market access tools

How This All Works — Our Unmet need framework

Discover the framework at the heart of our analysis and how we use it to predict patient share

Recent Insights

Our Take Blog

Feb 17, 2026

Chronic Diseases

Gene Therapies for Sickle Cell Disease: Expensive but Worth It

Feb 17, 2026

Chronic Diseases

Read More →

Feb 17, 2026

Chronic Diseases

Feb 13, 2026

Oncology

Keytruda Grabs its 42nd Approval in PD-L1+ PROC

Feb 13, 2026

Oncology

Read More →

Feb 13, 2026

Oncology

Plan for the Best, Prepare for the Worst - Handling Uncertainty in R&D

Feb 10, 2026

R&D Insights

Plan for the Best, Prepare for the Worst - Handling Uncertainty in R&D

Feb 10, 2026

R&D Insights

Read More →

Feb 10, 2026

R&D Insights

Finding the Best R&D Opportunities

Jan 27, 2026

R&D Insights

Finding the Best R&D Opportunities

Jan 27, 2026

R&D Insights

Read More →

Jan 27, 2026

R&D Insights

Using Equinox Drivers Charts to Understand Fabhalta's Success in PNH

Jan 8, 2026

Chronic Diseases

Using Equinox Drivers Charts to Understand Fabhalta's Success in PNH

Jan 8, 2026

Chronic Diseases

Read More →

Jan 8, 2026

Chronic Diseases

Measuring Risk in R&D

Dec 29, 2025

R&D Insights

Measuring Risk in R&D

Dec 29, 2025

R&D Insights

Read More →

Dec 29, 2025

R&D Insights

Want to read more? Click below